Biotie Therapies - Company Announcement

ACORDA THERAPEUTICS TO COMMENCE A COMPULSORY REDEMPTION PROCEEDING IN RESPECT OF THE REMAINING BIOTIE THERAPIES CORP. SHARES

BIOTIE THERAPIES CORP.         STOCK  EXCHANGE  RELEASE    20 April 2016, at
4.50 p.m. (EET)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, HONG KONG OR IN ANY OTHER JURISDICTION
IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW.

ACORDA THERAPEUTICS TO COMMENCE A COMPULSORY REDEMPTION PROCEEDING IN RESPECT OF
THE REMAINING BIOTIE THERAPIES CORP. SHARES

Acorda Therapeutics, Inc. (Nasdaq: ACOR) ("Acorda") has on 11 April 2016
announced that it will complete the tender offer to purchase all of the issued
and outstanding shares, American Depositary Shares, stock options, share units
and warrants in Biotie Therapies Corp (Nasdaq Helsinki: BTH1V; Nasdaq: BITI)
("Biotie" or the "Company") that are not owned by Biotie or any of its
subsidiaries.

Title to 92,36 percent of all the shares and votes in Biotie, excluding the
treasury shares held by Biotie, has now transferred to Acorda in accordance with
the terms and conditions of the tender offer. As a result, Acorda has today
informed Biotie that the redemption right and obligation under the Finnish
Limited Liability Companies Act in respect of the Biotie shares held by the
minority shareholders has arisen.

According to Acorda, it will initiate arbitral proceedings as provided in the
Finnish Limited Liability Companies Act to effectuate the redemption of the
Biotie shares held by minority shareholders. In such redemption proceeding, the
redemption price for the shares is EUR 0.2946 per Share, which is the same price
as the consideration paid by Acorda in the tender offer.


Turku, 20 April 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie is a biopharmaceutical company focused on products for neurodegenerative
and psychiatric disorders. Biotie's development has delivered Selincro
(nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being marketed across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional compounds which are
in Phase 2 development for cognitive disorders including Parkinson's disease
dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of
the liver.

INFORMATION REGARDING ACORDA

Founded in 1995, Acorda is a biotechnology company focused on developing
therapies that improve the lives of people with neurological disorders, with its
common stock listed on Nasdaq US.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including multiple sclerosis, Parkinson's
disease, post-stroke walking deficits, epilepsy and migraine. Acorda markets
three FDA-approved therapies, including AMPYRA (dalfampridine) Extended Release
Tablets, 10 mg.

ADDITIONAL INFORMATION

Investors  and holders of Biotie equity  securities are strongly advised to read
the  tender  offer  statement,  including  the  offer  to  purchase,  letter  of
transmittal,  acceptance forms and other related  tender offer documents and the
related  solicitation/recommendation statement on Schedule 14D-9 filed by Biotie
with  the United States Securities and  Exchange Commission (the "SEC"), because
they  contain important information. These documents  are available at no charge
on  the SEC's website  at www.sec.gov. In  addition, a copy  of the Tender Offer
Document  and related documents may be obtained free of charge at www.acorda.com
or Office of the Corporate Secretary, 420 Saw Mill River Road, Ardsley, New York
10502.

In  addition  to  the  Schedule  TO,  Acorda files annual, quarterly and special
reports,  proxy statements and other information with  the SEC. You may read and
copy  any reports, statements  or other information  filed by Acorda  at the SEC
public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call
the  SEC at 1-800-SEC-0330 for further information on the public reference room.
Acorda's  filings with the SEC are also  available to the public from commercial
document-retrieval  services  and  at  the  website  maintained  by  the  SEC at
www.sec.gov.

THE  TENDER OFFER  IS NOT  AND WILL  NOT BE  MADE DIRECTLY  OR INDIRECTLY IN ANY
JURISDICTION  WHERE EITHER  AN OFFER  OR PARTICIPATION  THEREIN IS PROHIBITED BY
APPLICABLE  LAW  OR  WHERE  ANY  TENDER  OFFER DOCUMENT OR REGISTRATION OR OTHER
REQUIREMENTS  WOULD APPLY  IN ADDITION  TO THOSE  UNDERTAKEN IN  FINLAND AND THE
UNITED STATES.

IN  ADDITION, THE TENDER OFFER DOCUMENT,  THE RELATED DOCUMENTS AND THIS RELEASE
WILL  NOT AND MAY NOT BE DISTRIBUTED,  FORWARDED OR TRANSMITTED INTO OR FROM ANY
JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW. IN PARTICULAR, THE TENDER OFFER
IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, CANADA, JAPAN, AUSTRALIA,
SOUTH  AFRICA OR HONG KONG. THE TENDER OFFER CANNOT BE ACCEPTED BY ANY SUCH USE,
MEANS  OR INSTRUMENTALITY OR FROM WITHIN  CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA
OR HONG KONG.

This release is for informational purposes only and does not constitute a tender
offer document or an offer, solicitation of an offer or an invitation to a sales
offer.  Potential investors in Finland shall accept the Tender Offer only on the
basis  of the information provided in the  Tender Offer Document approved by the
Finnish Financial Supervisory Authority and related materials.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this announcement are forward-looking
statements, including statements regarding the expected consummation of the
acquisition, which involves a number of risks and uncertainties, including the
satisfaction of closing conditions for the acquisition, such as the possibility
that the transaction will not be completed and other risks and uncertainties
discussed in the Tender Offer documents filed by Acorda and the
solicitation/recommendation statement filed by the Company. These statements are
based on current expectations, assumptions, estimates and projections, and
involve known and unknown risks, uncertainties and other factors that may cause
results, levels of activity, performance or achievements to be materially
different from any future statements. These statements are generally identified
by words or phrases such as "believe", "anticipate", "expect", "intend", "plan",
"will", "may", "should", "estimate", "predict", "potential", "continue" or the
negative of such terms or other similar expressions. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual results
and the timing of events may differ materially from the expected results and/or
timing discussed in the forward-looking statements, and you should not place
undue reliance on these statements. Acorda and the Company disclaim any intent
or obligation to update any forward-looking statements as a result of
developments occurring after the period covered by this announcement or
otherwise.


[HUG#2005184]